Answers are grounded in this paper and cite their sources.
This reveals a novel catalyst design for enhanced carbon dioxide reduction in nanocatalysts, indicating strong performance metrics.
Developing highly efficient catalyst for carbon dioxide reduction (CO 2 RR) to convert CO 2 into carbon-based chemicals and reduce anthropogenic carbon emission is desirable but challenging. In this work, a high-activity NiNC-2mIM catalyst has been developed via pyrolysis of 2-methylimidazole Ni-ZIF precursor, it exhibits excellent performance for CO 2 reduction producing CO, with Faradaic efficiency ( FE CO ) of about 98% and a current density of 55 mA cm -2 at -1.0 V (vs. RHE), outperforming the investigated NiNC-IM and NiNC-2eIM (derived from imidazole Ni ZIF precursor and 2-ethylimidazole Ni ZIF precursor, respectively) in this work and many previously reported Ni-based nanocatalysts. Mechanism studies demonstrate that 2-methylimidazole ligand induces higher content of pyridinic N species in the NiNC-2mIM catalyst, which enhances the affinity for CO 2 and provides low-polarity and high-activity Ni-N motif for CO 2 RR. This work develops a novel imidazole-based ZIF mediated regulation strategy for engineering pyridinic-N-rich N-doped carbon supported Ni nanocatalyst to highly efficiently catalyze CO 2 reduction producing CO.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: